The performance of tuberculin skin test (TST) and interferon-γ release assays (IGRAs) in predicting tuberculosis (TB).
Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?
Researchers evaluated the tolerability, safety, pharmacodynamics, and pharmacokinetic properties of muvalaplin.